IONQ Inc vs Liquidia Corporation Common Stock — how do they compare? IONQ Inc trades at $30.75 (market cap $12.73B), while Liquidia Corporation Common Stock trades at $34.2 (market cap $3.04B). The key difference: IONQ Inc is far larger — about 4.2× Liquidia Corporation Common Stock's market cap, and IONQ Inc is more actively traded (40,961,424 versus 21,111,778). Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 34 Days and Liquidia Corporation Common Stock for 0 Days on average.
| IONQ | LQDA | |
|---|---|---|
Market Cap | $12.73B | $3.04B |
Volume | 40,961,424 | 21,111,778 |
Sector | Technology | Health |
52-Week High | $72.41 | $91.03 |
52-Week Low | $26.59 | $22.02 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $10.66B | $2.94B |
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $34.73, down 4.25% today, with a bearish technical signal despite bullish oscillators. The company shows strong revenue growth (2025: $130M, 2026: $246M) but deep losses (2025: -$510M, 2026: -$1.4B), resulting in negative margins. Analyst consensus is bullish with a $65.20 price target (66.7% Buy ratings), supported by recent positive coverage from Bank of America and media optimism around quantum computing prospects.
Outlook: High growth potential in quantum computing with institutional backing, but profitability remains distant. Risks include cash burn, execution challenges, and rich valuations (P/S: 43.6). Investors must weigh long-term disruption potential against near-term financial strain.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →